Insmed (INSM) Osake Kurssi
Insmed Kurssi
Liikevaihto on kasvanut 40,2 % vuodessa viimeisten 19 vuoden aikana 606,42 M USD:een. Insmedn nettomarginaali on nyt −210,5 %, noussut −230,6 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 197,50 USD, eli yli nykyhintaa 94,1 %. 30 analyytikosta 29 suosittaa ostoa — kokonaiskonsensus on Osta.
Insmed osakekurssi
Insmed liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Insmed -osakkeesta
Insmed Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for patients with serious and rare diseases. The company's business model revolves around identifying unmet medical needs and utilizing innovative technologies to develop novel therapies. Insmed focuses on advanced lung diseases, including non-tuberculous mycobacterial lung disease (NTM) and severe bronchiectasis. By leveraging its expertise in this therapeutic area, Insmed aims to provide effective treatments to patients who lack adequate options. With a strong commitment to research and development, Insmed Inc strives to make a positive impact on the lives of patients and continually advance the field of biopharmaceuticals.
Insmed Inc is primarily active in the biopharmaceutical industry, specializing in the development and commercialization of novel therapies for patients with serious and rare diseases. With a focus on respiratory and infectious diseases, Insmed Inc aims to address unmet medical needs and improve the lives of patients. As a leading player in the biopharmaceutical sector, Insmed Inc is committed to advancing innovative solutions and creating value for shareholders, healthcare providers, and patients alike.
The main competitors of Insmed Inc in the market include other pharmaceutical companies such as Gilead Sciences, Novartis, AstraZeneca, and GlaxoSmithKline. These companies operate in the same industry and compete with Insmed Inc in the development and commercialization of innovative therapies. Their products and services may overlap with Insmed Inc's, creating competition for market share and the pursuit of specific indications and patient populations. By staying informed about the activities and progress of these competitors, investors can gain insights into the dynamic landscape of the pharmaceutical industry and make more informed investment decisions.
Insmed Inc is a biopharmaceutical company headquartered in Bridgewater, New Jersey. Founded in 1988, Insmed focuses on the development and commercialization of therapies for serious and rare diseases. The company primarily concentrates on the discovery and development of novel drugs to address unmet medical needs, particularly in the field of severe lung diseases. Over the years, Insmed has made significant advancements in scientific research and clinical trials, resulting in the approval of its flagship product, ARIKAYCE®, for the treatment of Mycobacterium avium complex lung disease. With a strong commitment to innovation and improving patients' lives, Insmed Inc has established itself as a leading player in the biopharmaceutical industry.
Insmed Inc, a leading biopharmaceutical company, has accomplished several significant milestones. In recent years, Insmed Inc received FDA approval for its breakthrough drug, ARIKAYCE®, a treatment for Mycobacterium avium complex (MAC) lung disease. This achievement marked a major breakthrough in respiratory medicine. Additionally, Insmed Inc has successfully advanced the development of novel therapies, such as brensocatib for bronchiectasis, establishing its position as a pioneer in the field. Through its dedication to scientific innovation and commitment to improving patient outcomes, Insmed Inc continues to achieve remarkable milestones, reinforce its reputation, and shape the future of the healthcare industry.
Insmed Inc is primarily present in the United States.
Insmed Inc is a leading biopharmaceutical company committed to transforming the lives of patients with serious and rare diseases. With a strong corporate philosophy centered around innovation, collaboration, and patient-centricity, Insmed strives to deliver breakthrough therapies that address unmet medical needs. The company values integrity, scientific excellence, and empathy, aiming to make a positive impact on the lives of patients worldwide. Insmed Inc focuses on developing advanced therapies using its proprietary platform technologies and leveraging its extensive industry knowledge and expertise. By constantly pushing boundaries and advocating for patients, Insmed embodies a commitment to improving healthcare outcomes and enhancing the quality of life for those in need.
Analyytikot asettavat tällä hetkellä Insmed-osakkeelle keskimääräisen tavoitehinnan 197,43 USD (mediaani: 197,50 USD), mikä merkitsee +94,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 30 analyytikkoarvioon.
30 analyytikkoa arvioi tällä hetkellä Insmed-osaketta: 29 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Insmed-yhtiöltä 1,80 Mrd. USD liikevaihtoa ja −1,59 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Insmed-osake noteerataan hintaan 90,85 EUR (101,74 USD).
Insmed-osake (INSM) on listattuna 5 pörssissä, muun muassa: NASDAQ (INSM), London (0JAV.L), SIX (Zürich) (IM8N.SW), Frankfurt (IM8N.F).
Insmed Inc is a biopharmaceutical company focused on developing and marketing therapies for patients with rare lung diseases and serious infections. The company operates in three core business areas: product development, marketing of approved therapies, and diagnostic services. Insmed Inc invests heavily in research and development, particularly in the potential of inhalation drugs for targeted treatment of lung diseases such as cystic fibrosis and non-tuberculous mycobacterial infections. They also market approved therapies, like Arikayce, and offer diagnostic services with an innovative lung function diagnostic system. The goal of their business model is to create value for patients, doctors, and investors, positioning themselves as a leading company in this field. However, regulatory conditions may pose risks and delay the market entry of new therapies. Overall, Insmed Inc is an exciting company of great interest to investors and the medical community, contributing to saving lives and improving the quality of life for patients worldwide.
odotettu liikevaihto Insmed on 1,80 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Insmed on −340,60 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Insmed:n hinta-voitto-suhde (P/E) on tällä hetkellä −63,81. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Insmed-osakkeen arvostusta.
Insmed:n hinta-myynti-suhde (P/S) on tällä hetkellä 12,06. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Insmed-osakkeen arvostuskennuslukuna.
Insmed:n Eulpool-laatuscore on 4/10.
Insmed:n ISIN on US4576693075. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Insmed:n WKN on A1JJA3. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Insmed:n ticker on INSM. Tämä pörssinoteeraus käytetään Insmed-osakkeiden kauppaan pörssissä.
Insmed osake
Insmed vertaisryhmä
Insmed Ticker
Insmed FIGI
Kaikki tunnusluvut ja syvällinen analyysi Insmed:sta
Meidän osakeanalyysimme Insmed-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Insmed:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: